HK1187605A1 - Pyrazole aminopyrimidine derivatives as lrrk2 modulators lrrk2 - Google Patents

Pyrazole aminopyrimidine derivatives as lrrk2 modulators lrrk2

Info

Publication number
HK1187605A1
HK1187605A1 HK14100468.7A HK14100468A HK1187605A1 HK 1187605 A1 HK1187605 A1 HK 1187605A1 HK 14100468 A HK14100468 A HK 14100468A HK 1187605 A1 HK1187605 A1 HK 1187605A1
Authority
HK
Hong Kong
Prior art keywords
lrrk2
modulators
aminopyrimidine derivatives
pyrazole
pyrazole aminopyrimidine
Prior art date
Application number
HK14100468.7A
Other languages
English (en)
Chinese (zh)
Inventor
查爾斯．貝克-格倫
丹尼爾．喬恩．伯狄克
馬克．錢伯斯
陳慧芬
安東尼．埃斯特拉德
扎卡里．凱文．斯威尼
布萊恩．
．尚
Original Assignee
霍夫曼-拉羅奇有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 霍夫曼-拉羅奇有限公司 filed Critical 霍夫曼-拉羅奇有限公司
Publication of HK1187605A1 publication Critical patent/HK1187605A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK14100468.7A 2010-11-10 2014-01-16 Pyrazole aminopyrimidine derivatives as lrrk2 modulators lrrk2 HK1187605A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41227310P 2010-11-10 2010-11-10
US201161546613P 2011-10-13 2011-10-13
PCT/EP2011/069696 WO2012062783A1 (fr) 2010-11-10 2011-11-09 Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2

Publications (1)

Publication Number Publication Date
HK1187605A1 true HK1187605A1 (en) 2014-04-11

Family

ID=44983512

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14100468.7A HK1187605A1 (en) 2010-11-10 2014-01-16 Pyrazole aminopyrimidine derivatives as lrrk2 modulators lrrk2

Country Status (28)

Country Link
US (1) US8815882B2 (fr)
EP (3) EP3124483B1 (fr)
JP (3) JP5986094B2 (fr)
KR (1) KR101566091B1 (fr)
CN (1) CN103313978B (fr)
AR (1) AR083813A1 (fr)
AU (1) AU2011328139A1 (fr)
BR (1) BR112013011600B1 (fr)
CA (2) CA2812669C (fr)
CY (1) CY1120073T1 (fr)
DK (2) DK2638031T3 (fr)
EC (1) ECSP13012611A (fr)
ES (2) ES2746134T3 (fr)
HK (1) HK1187605A1 (fr)
HR (2) HRP20172006T1 (fr)
HU (2) HUE046617T2 (fr)
IL (1) IL225234A0 (fr)
LT (2) LT3124483T (fr)
MA (1) MA34644B1 (fr)
MX (1) MX2013005199A (fr)
NO (1) NO2638031T3 (fr)
PL (2) PL2638031T3 (fr)
PT (2) PT3124483T (fr)
RS (2) RS56583B1 (fr)
SG (1) SG189043A1 (fr)
SI (2) SI2638031T1 (fr)
TW (1) TW201302733A (fr)
WO (1) WO2012062783A1 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017140639A (ru) 2011-05-23 2019-02-12 Элан Фармасьютикалз, Инк. Ингибиторы активности киназы lrrk2
AR089182A1 (es) 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
BR112014011850B1 (pt) 2011-11-29 2022-01-11 Genentech, Inc Derivados de aminopirimidina, seus usos, e composição farmacêutica
US20140228384A1 (en) * 2011-11-29 2014-08-14 Genentech, Inc. Assays and biomarkers for lrrk2
BR112014011219B1 (pt) * 2011-11-29 2022-08-23 Genentech, Inc. Derivados de aminopirimidina, seus usos, e composição farmacêutica
US8791130B2 (en) * 2011-11-29 2014-07-29 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 modulators
US9139566B2 (en) 2011-11-30 2015-09-22 Genentech, Inc. Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (PET) imaging for LRRK2
BR112014027117B1 (pt) * 2012-05-03 2022-09-06 Genentech, Inc Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição
KR102091894B1 (ko) * 2012-05-03 2020-03-20 제넨테크, 인크. Lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체
EP3255049A1 (fr) 2012-06-29 2017-12-13 Pfizer Inc Nouvelles 7h-pyrrolo[2,3-d]pyrimidines substituées par un groupe amino en position 4, utilisées comme inhibiteurs de lrrk2
WO2014060381A1 (fr) 2012-10-18 2014-04-24 Bayer Cropscience Ag Composés hétérocycliques pour la lutte contre les nuisibles
WO2017156493A1 (fr) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Composés, compositions et procédés
WO2014134772A1 (fr) * 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine
EP3083591B1 (fr) 2013-12-17 2018-01-03 Merck Patent GmbH Dérivés n1-(3,3,3-trifluoro-2-hydroxo-2-méthylpropionyl)-pipéridine en tant qu'inhibiteurs de pyruvate déshydrogénase kinase
WO2015092592A1 (fr) 2013-12-17 2015-06-25 Pfizer Inc. Nouvelles 1h-pyrrolo[2,3- b]pyridines 3,4-disubstituées et 7h-pyrrolo[2,3-c]pyridazines 4,5-disubstituées en tant qu'inhibiteurs de la lrrk2
EP3082819B1 (fr) 2013-12-20 2020-06-17 Signal Pharmaceuticals, LLC Composés substitués de diaminopyrimidyle, compositions à base de ceux-ci, et méthodes de traitement les utilisant
EA029774B1 (ru) 2014-01-29 2018-05-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения
CA2937430A1 (fr) 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Composes
JP6517319B2 (ja) * 2014-03-28 2019-05-22 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ 置換されたヘテロアリール化合物および使用方法
EP2927221A1 (fr) * 2014-03-31 2015-10-07 Commonwealth Scientific and Industrial Research Organisation Composés de complexes métalliques phosphorescents à base de diazaborole et dispositifs électroluminescents
WO2015170600A1 (fr) * 2014-05-08 2015-11-12 東ソー・エフテック株式会社 Dérivé de 5-(trifluorométhyl)pyrimidine et son procédé de production
US10058559B2 (en) 2014-05-15 2018-08-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Treatment or prevention of an intestinal disease or disorder
JP6262079B2 (ja) * 2014-06-02 2018-01-17 東ソー・ファインケム株式会社 ４−（２，２，２−トリフルオロエトキシ）−５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法
JP6431294B2 (ja) * 2014-06-16 2018-11-28 東ソー・ファインケム株式会社 ５−（トリフルオロメチル）ピリミジン誘導体及びその製造法
US10059689B2 (en) 2014-10-14 2018-08-28 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
CN108779093B (zh) 2016-03-29 2021-03-09 默克专利股份公司 作为丙酮酸脱氢酶激酶的抑制剂的n1-(3,3,3-三氟-2-羟基-2-甲基丙酰基)-哌啶衍生物
US10428024B2 (en) 2016-04-28 2019-10-01 Merck Patent Gmbh Piperidinyl derivatives
PE20240221A1 (es) * 2016-06-16 2024-02-16 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
CN106588884B (zh) * 2016-11-10 2019-04-09 浙江大学 2-多取代芳环-嘧啶类衍生物及制备和医药用途
CN106588885B (zh) * 2016-11-10 2019-03-19 浙江大学 2-取代芳环-嘧啶类衍生物及制备和应用
EP3586848B1 (fr) 2017-02-24 2021-09-01 Daegu-Gyeongbuk Medical Innovation Foundation Composition pharmaceutique comprenant un composé apte à traverser la barrière hémato-encéphalique en tant que principe actif pour prévenir ou traiter le cancer du cerveau
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
US20200157081A1 (en) * 2017-05-24 2020-05-21 Denali Therapeutics Inc. Compounds, compositions and methods
UA127517C2 (uk) * 2017-06-30 2023-09-20 Емджен Інк. Синтез омекамтиву мекарбілу
CA3069554A1 (fr) * 2017-07-14 2019-01-17 Glaxosmithkline Intellectual Property Development Limited Inhibiteurs de la kinase 2 a repetition riche en leucine
EP3710006A4 (fr) 2017-11-19 2021-09-01 Sunshine Lake Pharma Co., Ltd. Composés hétéroaryle substitués et leurs méthodes d'utilisation
AR113893A1 (es) * 2017-11-21 2020-06-24 Denali Therapeutics Inc Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción
AU2018392599A1 (en) * 2017-12-20 2020-07-09 Denali Therapeutics Inc. Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
WO2019160037A1 (fr) * 2018-02-14 2019-08-22 国立大学法人 東京大学 Procédés de production de composés à l'aide d'halogénure d'acide
EP3886854A4 (fr) 2018-11-30 2022-07-06 Nuvation Bio Inc. Composés pyrrole et pyrazole et leurs procédés d'utilisation
AR118641A1 (es) * 2019-04-11 2021-10-20 Denali Therapeutics Inc Compuestos, composiciones y métodos
MX2021014705A (es) * 2019-05-31 2022-04-06 Denali Therapeutics Inc Formulacion de liberacion modificada de un compuesto de pirimidinilamino-pirazol y metodos de tratamiento.
CN110627810B (zh) * 2019-06-05 2024-05-10 中国医学科学院药用植物研究所 一种三氟甲基吡唑衍生物的制备方法
US20230131830A1 (en) * 2020-03-06 2023-04-27 National Health Research Institutes Pyrimidine compounds and their pharmaceutical uses
AU2021243887A1 (en) 2020-03-23 2022-11-03 Korea Research Institute Of Chemical Technology Novel pyrimidine derivative, and composition for preventing or treating neurodegenerative diseases and cancer, comprising same
KR102342803B1 (ko) 2020-03-23 2021-12-24 환인제약 주식회사 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물
WO2022084210A1 (fr) 2020-10-20 2022-04-28 F. Hoffmann-La Roche Ag Polythérapie à base d'antagonistes de liaison à l'axe pd-1 et d'inhibiteurs de lrrk2
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
EP4308115A1 (fr) * 2021-03-17 2024-01-24 Merck Sharp & Dohme LLC Amides d'hétéroaroyle en tant qu'inhibiteurs de lrrk2, compositions pharmaceutiques et utilisations associées
WO2022204721A1 (fr) * 2021-03-26 2022-09-29 Sumitomo Pharma Oncology, Inc. Inhibiteurs d'alk-5 et leurs utilisations
WO2023076404A1 (fr) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Méthodes de traitement de lupus érythémateux disséminé
WO2023174946A1 (fr) 2022-03-15 2023-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode précoce et non invasive d'évaluation du risque de maladie de parkinson chez un sujet
WO2023224894A1 (fr) * 2022-05-20 2023-11-23 Merck Sharp & Dohme Llc Macrocycles servant d'inhibiteurs de lrrk2, compositions pharmaceutiques et leurs utilisations
WO2024097394A1 (fr) 2022-11-03 2024-05-10 Denali Therapeutics Inc. Formes solides et co-cristallines d'un composé de pyrimidine triazole
WO2024112746A1 (fr) 2022-11-22 2024-05-30 Denali Therapeutics Inc. Procédés et intermédiaires pour la préparation d'un composé pyrimidine aminopyrazole
CN115819405A (zh) * 2022-12-20 2023-03-21 沪渝人工智能研究院 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用
CN118546132A (zh) * 2023-02-27 2024-08-27 科辉智药(深圳)新药研究中心有限公司 亚砜酰亚胺化合物及其作为lrrk2蛋白激酶抑制剂的应用

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ101496A3 (en) 1993-10-12 1996-11-13 Du Pont Merck Pharma N-alkyl-n-aryl-pyrimidinamines and derivatives thereof
WO1995010506A1 (fr) 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyle-n-arylpyrimidinamines et leurs derives
BRPI9909191B8 (pt) 1998-03-27 2021-07-06 Janssen Pharmaceutica Nv derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende
US6458823B1 (en) 1998-06-08 2002-10-01 Wyeth Diaminopyrazoles
US6172222B1 (en) 1998-06-08 2001-01-09 American Home Products Corporation Diaminopyrazoles
KR100658489B1 (ko) 1998-11-10 2006-12-18 얀센 파마슈티카 엔.브이. Ｈｉｖ 복제를 억제하는 피리미딘
BR0013551A (pt) 1999-08-13 2003-06-17 Vertex Pharma Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas
PT1225874E (pt) 1999-09-24 2006-06-30 Janssen Pharmaceutica Nv Composicoes antivirais.
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
CA2406562C (fr) 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Pyrimidines et triazines inhibant la replication du vih
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
CN100355750C (zh) 2000-09-15 2007-12-19 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的吡唑化合物
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1343781B1 (fr) 2000-12-05 2008-09-03 Vertex Pharmaceuticals Incorporated Inhibiteurs de kinases c-jun n-terminales (jnk) et d'autres proteines kinases
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
ATE326462T1 (de) 2000-12-21 2006-06-15 Vertex Pharma Pyrazolverbindungen als protein-kinase- inhibitoren
WO2002059110A1 (fr) 2000-12-21 2002-08-01 Glaxo Group Limited Composes chimiques
US6884804B2 (en) 2001-05-16 2005-04-26 Vertex Pharmaceuticals Incorporated Inhibitors of Src and other protein kinases
KR100874791B1 (ko) 2001-05-29 2008-12-18 바이엘 쉐링 파마 악티엔게젤샤프트 Ｃｄｋ-억제 피리미딘, 그의 제조방법 및 약제로서의 용도
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
HUP0402352A2 (hu) 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
US6878697B2 (en) 2001-06-21 2005-04-12 Ariad Pharmaceuticals, Inc. Phenylamino-pyrimidines and uses thereof
CA2451128A1 (fr) 2001-06-26 2003-01-09 Bristol-Myers Squibb Company Inhibiteurs n-heterocycliques d'expression tnf-alpha
WO2003030909A1 (fr) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer
WO2003040141A1 (fr) 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Composes d'oxazolyl-phenyl-2,4-diamino-pyrimidine, et methodes de traitement de troubles hyperproliferatifs
WO2003032994A2 (fr) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Nouvelles pyrimidines substituees, procede permettant de les produire et leur utilisation comme medicament
CA2463989C (fr) 2001-10-17 2012-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Derives pyrimidine, compositions pharmaceutiques contenant ces composes, utilisation et procede de fabrication de ces composes
AU2002367172A1 (en) 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
AU2003212282A1 (en) * 2002-03-11 2003-09-22 Schering Aktiengesellschaft Cdk inhibiting 2-heteroaryl pyrimidine, the production thereof, and use thereof as a medicament
US7288547B2 (en) 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
AR039540A1 (es) 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2004048343A1 (fr) 2002-11-28 2004-06-10 Schering Aktiengesellschaft Pyrimidines inhibitrices de chk-, pdk- et de akt, production et utilisation de ces composes comme agents pharmaceutiques
US20040242613A1 (en) 2003-01-30 2004-12-02 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
AU2004240720A1 (en) 2003-05-21 2004-12-02 Bayer Cropscience Aktiengesellschaft Iodopyrazolyl carboxanilides
CA2531490A1 (fr) 2003-07-15 2005-02-03 Neurogen Corporation Analogues de pyrimidine-4-ylamine substitues constituant des ligands des recepteurs vanilloides
NZ545270A (en) * 2003-07-30 2010-04-30 Rigel Pharmaceuticals Inc 2,4-Pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
WO2005012298A1 (fr) 2003-07-30 2005-02-10 Cyclacel Limited Derives de pyridinylamino-pyrimidine utiles comme inhibiteurs de la proteine kinase
EP1663242B1 (fr) 2003-08-07 2011-04-27 Rigel Pharmaceuticals, Inc. Composes de 2,4-pyrimidinediamine et leurs utilisations comme agents antiproliferants
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
WO2005111016A1 (fr) 2004-05-14 2005-11-24 Pfizer Products Inc. Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
JP4812763B2 (ja) 2004-05-18 2011-11-09 ライジェル ファーマシューティカルズ， インコーポレイテッド シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
EP1598343A1 (fr) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH Dérivés de 2-arylaminopyrimidines comme des inhibiteurs de PLK
EP1765791A1 (fr) 2004-07-08 2007-03-28 Boehringer Ingelheim Pharmaceuticals Inc. Dérivés de pyrimidine utiles comme inhibiteurs de la pkc-thêta
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
US20060058525A1 (en) 2004-09-01 2006-03-16 Rajinder Singh Synthesis of 2,4-pyrimidinediamine compounds
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
ES2380550T3 (es) 2004-11-24 2012-05-16 Rigel Pharmaceuticals, Inc. Compuestos de espiro-2,4-pirimidindiamina y sus usos
EP1828183A1 (fr) 2004-12-17 2007-09-05 AstraZeneca AB 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides en tant qu'inhibiteurs de cdk
JP5208516B2 (ja) 2004-12-30 2013-06-12 エグゼリクシス， インコーポレイテッド キナーゼモジュレーターとしてのピリミジン誘導体および使用方法
DE102005008310A1 (de) 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
EP1705177A1 (fr) 2005-03-23 2006-09-27 Schering Aktiengesellschaft Pyrimidines substituées par une N-aryl-sulfoximine comme inhibiteurs de CDK et de VEGF, leur préparation et utilisation comme médicaments
CN101218229A (zh) 2005-05-05 2008-07-09 阿斯利康(瑞典)有限公司 吡唑基-氨基取代的嘧啶及其在癌症治疗中的应用
KR101312225B1 (ko) 2005-06-08 2013-09-26 리겔 파마슈티칼스, 인크. Ｊａｋ 경로의 억제를 위한 조성물 및 방법
WO2006135915A2 (fr) 2005-06-13 2006-12-21 Rigel Pharmaceuticals, Inc. Methodes et compositions de traitement de maladies osseuses degeneratives
AU2006259525B2 (en) 2005-06-14 2012-05-24 Gpcr Therapeutics, Inc Pyrimidine compounds
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
WO2007023382A2 (fr) 2005-08-25 2007-03-01 Pfizer Inc. Composes de pyrimidine amino pyrazole, puissants inhibiteurs de kinase
US20100069387A1 (en) 2005-09-07 2010-03-18 Palmer Stephen S IKK Inhibitors for the Treatment of Endometriosis
US20090149467A1 (en) * 2005-09-15 2009-06-11 Merck & Co., Inc. Tyrosine Kinase Inhibitors
DE102005048072A1 (de) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
WO2007129195A2 (fr) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazoles
AR060890A1 (es) 2006-05-15 2008-07-23 Boehringer Ingelheim Int Compuestos derivados de pirimidina y composicion farmaceutica en base a ellos
DE102006027156A1 (de) 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
MX2008016007A (es) 2006-06-15 2009-01-16 Boehringer Ingelheim Int 2-anilino-4-aminoalquilenoaminopirimidinas.
WO2007149789A2 (fr) 2006-06-22 2007-12-27 Applera Corporation Conversion d'amplification spécifique à une cible en séquençage universel
WO2008016675A1 (fr) 2006-08-01 2008-02-07 Praecis Pharmaceuticals Incorporated Inhibiteurs de kinases p38
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
US20080194575A1 (en) 2006-10-04 2008-08-14 Naiara Beraza Treatment for non-alcoholic-steatohepatitis
CA2669128C (fr) 2006-11-27 2011-07-12 Ares Trading S.A. Traitement du myelome multiple
AU2007333394C1 (en) 2006-12-08 2011-08-18 Novartis Ag Compounds and compositions as protein kinase inhibitors
GB0625196D0 (en) 2006-12-18 2007-01-24 7Tm Pharma As Modulators of cannabinoid receptor
CA2670645A1 (fr) 2006-12-19 2008-07-03 Genentech, Inc. Inhibiteurs de pyrimidine kinase
EP1939185A1 (fr) 2006-12-20 2008-07-02 Bayer Schering Pharma Aktiengesellschaft Nouveaux hetaryl-phénylènediamine-pyrimidines en tant qu'inhibiteurs de protéine kinase pour le traitement du cancer
WO2008077885A2 (fr) 2006-12-22 2008-07-03 Boehringer Ingelheim International Gmbh Nouveaux composés
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
UY31048A1 (es) 2007-04-25 2008-11-28 Astrazeneca Ab Nuevos compuestos de pirimidina y usos de los mismos
JP2010529959A (ja) 2007-06-08 2010-09-02 バイエル・クロツプサイエンス・エス・アー 殺菌剤ヘテロシクリル−ピリミジニル−アミノ誘導体
CN101903357A (zh) 2007-07-17 2010-12-01 里格尔药品股份有限公司 作为pkc抑制剂的环状胺取代的嘧啶二胺
JP5410432B2 (ja) 2007-09-28 2014-02-05 サイクラセル リミテッド プロテインキナーゼ阻害剤としてのピリミジン誘導体
ATE532773T1 (de) 2007-10-09 2011-11-15 Dow Agrosciences Llc Insektizide pyrimidinyl-aryl-hydrazone
UA104849C2 (uk) 2007-11-16 2014-03-25 Інсайт Корпорейшн 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus
WO2009071535A1 (fr) 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Nouveaux composés
WO2009071701A1 (fr) 2007-12-07 2009-06-11 Novartis Ag Dérivés de pyrazole et leur utilisation comme inhibiteurs de kinases dépendantes des cyclines
WO2009103032A1 (fr) 2008-02-15 2009-08-20 Rigel Pharmaceuticals, Inc. Composés de pyrimidine-2-amine et leur utilisation en tant qu’inhibiteurs des kinases jak
CL2009000600A1 (es) 2008-03-20 2010-05-07 Bayer Cropscience Ag Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
US20100056524A1 (en) 2008-04-02 2010-03-04 Mciver Edward Giles Compound
WO2009127642A2 (fr) * 2008-04-15 2009-10-22 Cellzome Limited Utilisation d’inhibiteurs de lrrk2 pour maladies neurodégénératives
EP2300013B1 (fr) 2008-05-21 2017-09-06 Ariad Pharmaceuticals, Inc. Dérivés phosphorés servant d'inhibiteurs de kinase
WO2009158348A1 (fr) 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. Dérivés 2-hétérocyclylaminoalkyl-(p-quinone) pour traiter les maladies liées à un stress oxydatif
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors
PE20100087A1 (es) 2008-06-25 2010-02-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP2318377B1 (fr) 2008-07-31 2013-08-21 Genentech, Inc. Composés de pyrimidine, compositions et procédés d'utilisation
CA2735730A1 (fr) 2008-09-01 2010-03-04 Astellas Pharma Inc. Compose 2,4-diaminopyrimidine
EP2161259A1 (fr) 2008-09-03 2010-03-10 Bayer CropScience AG 4-haloalkyle-diaminopyrimidines substitués
JP2012501978A (ja) 2008-09-03 2012-01-26 バイエル・クロップサイエンス・アーゲー 殺菌剤としてのヘテロ環置換アニリノピリミジン類
BRPI0918293A2 (pt) 2008-09-03 2019-09-24 Bayer Cropscience Ag anilinopirimidinas heterociclicamente substituídas como fungicidas
WO2010028179A1 (fr) 2008-09-03 2010-03-11 Dr. Reddy's Laboratories Ltd. Composés hétérocycliques comme modulateurs de gata
EP2330904A2 (fr) 2008-09-03 2011-06-15 Bayer CropScience AG Diaminopyrimidines a substitution alkyle en 4
US20100137313A1 (en) 2008-10-03 2010-06-03 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
UY32240A (es) 2008-11-14 2010-06-30 Boeringer Ingelheim Kg Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
GB0821307D0 (en) 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
CA2748181C (fr) 2009-01-06 2019-07-16 Nathanael S. Gray Composes pyrimido-diazepinone d'echafaudage de kinase et procedes de traitement de troubles
US20110071158A1 (en) 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
RU2011143740A (ru) * 2009-03-30 2013-05-10 Астеллас Фарма Инк. Соединение пиримидина
CA2758614A1 (fr) 2009-04-14 2010-10-21 Cellzome Limited Composes de pyrimidine substitues par fluoro en tant qu'inhibiteurs de jak3
CA2760794C (fr) 2009-05-05 2017-07-25 Dana Farber Cancer Institute Inhibiteurs d'egfr et procedes de traitement de troubles
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
JP2012529522A (ja) 2009-06-10 2012-11-22 アボット・ラボラトリーズ キナーゼ阻害剤としての２−（１ｈ−ピラゾール−４−イルアミノ）−ピリミジン
EP2440534A2 (fr) 2009-06-10 2012-04-18 Cellzome Limited Dérivés de pyrimidine en tant qu'inhibiteurs zap-70
AR077033A1 (es) 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
US20120165332A1 (en) 2009-06-18 2012-06-28 Cellzome Limited Sulfonamides and sulfamides as zap-70 inhibitors
US20120172384A1 (en) 2009-06-18 2012-07-05 Mihiro Sunose Heterocyclylaminopyrimidines as kinase inhibitors
WO2011034907A2 (fr) 2009-09-16 2011-03-24 Avila Therapeutics, Inc. Conjugués et inhibiteurs de protéine kinase
ES2512727T3 (es) 2009-09-29 2014-10-24 Glaxo Group Limited Nuevos compuestos
CN102811619B (zh) 2009-11-13 2015-04-22 金纳斯克公司 激酶抑制剂
PL2519543T3 (pl) 2009-12-29 2016-12-30 Białka wiążące heterodimery i ich zastosowania
US8470820B2 (en) 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives
CN103038230B (zh) * 2010-06-04 2016-05-25 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的氨基嘧啶衍生物
BR112014011219B1 (pt) * 2011-11-29 2022-08-23 Genentech, Inc. Derivados de aminopirimidina, seus usos, e composição farmacêutica
US8791130B2 (en) * 2011-11-29 2014-07-29 Genentech, Inc. Aminopyrimidine derivatives as LRRK2 modulators
AR089182A1 (es) * 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
BR112014011850B1 (pt) * 2011-11-29 2022-01-11 Genentech, Inc Derivados de aminopirimidina, seus usos, e composição farmacêutica
US9139566B2 (en) * 2011-11-30 2015-09-22 Genentech, Inc. Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (PET) imaging for LRRK2

Also Published As

Publication number Publication date
JP2018109038A (ja) 2018-07-12
MX2013005199A (es) 2013-06-28
SG189043A1 (en) 2013-05-31
EP3590933A1 (fr) 2020-01-08
EP2638031B1 (fr) 2017-10-11
RS59106B1 (sr) 2019-09-30
WO2012062783A1 (fr) 2012-05-18
HRP20191781T1 (hr) 2019-12-27
CA3017869C (fr) 2021-07-27
BR112013011600A8 (pt) 2021-09-08
SI2638031T1 (en) 2018-02-28
KR20130093657A (ko) 2013-08-22
HUE046617T2 (hu) 2020-03-30
PL2638031T3 (pl) 2018-03-30
IL225234A0 (en) 2013-06-27
US8815882B2 (en) 2014-08-26
MA34644B1 (fr) 2013-11-02
AR083813A1 (es) 2013-03-27
EP3124483A1 (fr) 2017-02-01
BR112013011600B1 (pt) 2022-01-11
CA2812669C (fr) 2018-11-06
CN103313978A (zh) 2013-09-18
ECSP13012611A (es) 2013-07-31
PT3124483T (pt) 2019-10-02
NO2638031T3 (fr) 2018-03-10
EP3590933B1 (fr) 2021-01-06
HUE037844T2 (hu) 2018-09-28
US20120157427A1 (en) 2012-06-21
KR101566091B1 (ko) 2015-11-04
CA2812669A1 (fr) 2012-05-18
LT2638031T (lt) 2017-12-11
BR112013011600A2 (pt) 2016-08-09
CA3017869A1 (fr) 2012-05-18
LT3124483T (lt) 2019-09-25
ES2746134T3 (es) 2020-03-04
JP5986094B2 (ja) 2016-09-06
JP6298115B2 (ja) 2018-03-20
DK2638031T3 (en) 2017-12-11
HRP20172006T1 (hr) 2018-02-09
EP3124483B1 (fr) 2019-07-10
PL3124483T3 (pl) 2020-03-31
ES2653967T3 (es) 2018-02-09
TW201302733A (zh) 2013-01-16
RS56583B1 (sr) 2018-02-28
AU2011328139A1 (en) 2013-04-04
JP2013545741A (ja) 2013-12-26
CY1120073T1 (el) 2018-12-12
EP2638031A1 (fr) 2013-09-18
JP2017008074A (ja) 2017-01-12
PT2638031T (pt) 2018-01-03
DK3124483T3 (da) 2019-09-02
JP6524284B2 (ja) 2019-06-05
SI3124483T1 (sl) 2019-10-30
CN103313978B (zh) 2015-04-15
EP2638031B9 (fr) 2020-01-08

Similar Documents

Publication Publication Date Title
HRP20160771T1 (hr) Derivati aminopirimidina kao modulatori za lrrk2
HK1187605A1 (en) Pyrazole aminopyrimidine derivatives as lrrk2 modulators lrrk2
HK1200820A1 (zh) 作為 調節劑的吡唑氨基嘧啶衍生物
HK1210778A1 (en) Pyrimidine pyrazolyl derivatives
AP2948A (en) Thienopyrmidinedione derivatives as TRPA1 modulators
HK1166081A1 (en) Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
HK1200819A1 (en) Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinsons disease lrrk2
ZA201304282B (en) Pyrazole derivative
ZA201209029B (en) Novel pyrimidine derivatives
HK1191862A1 (zh) 吡唑衍生物
HK1201836A1 (en) Novel pyrrole derivatives
EP2542075A4 (fr) Dérivés de fluorouracile
GB201106796D0 (en) Pyrrole derivatives